journal article·2016Open access

Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems

Susanne R. Youngren-Ortiz, Nishant S. Gandhi, Laura España-Serrano, Mahavir B. Chougule

KONA Powder and Particle Journal· Volume 33· Issue 0

Abstract

This article reviews the pulmonary route of administration, aerosol delivery devices, characterization of pulmonary drug delivery systems, and discusses the rationale for inhaled delivery of siRNA. Diseases with known protein malfunctions may be mitigated through the use of siRNA therapeutics. The inhalation route of administration provides local delivery of siRNA therapeutics for the treatment of various pulmonary diseases, however barriers to pulmonary delivery and intracellular delivery of siRNA exists. siRNA loaded nanocarriers can be used to overcome the barriers associated with the pulmonary route, such as anatomical barriers, mucociliary clearance, and alveolar macrophage clearance. Apart from naked siRNA aerosol delivery, previously studied siRNA carrier systems comprise of lipidic, polymeric, peptide, or inorganic origin. Such siRNA delivery systems formulated as aerosols can be successfully delivered via an inhaler or nebulizer to the pulmonary region. Preclinical animal investigations of inhaled siRNA therapeutics rely on intratracheal and intranasal siRNA and siRNA nanocarrier delivery. Aerosolized siRNA delivery systems may be characterized using in vitro techniques, such as dissolution test, inertial cascade impaction, delivered dose uniformity assay, laser diffraction, and laser Doppler velocimetry. The ex vivo techniques used to characterize pulmonary administered formulations include the isolated perfused lung model. In vivo techniques like gamma scintigraphy, 3D SPECT, PET, MRI, fluorescence imaging and pharmacokinetic/pharmacodynamics analysis may be used for evaluation of aerosolized siRNA delivery systems. The use of inhalable siRNA delivery systems encounters barriers to their delivery, however overcoming the barriers while formulating a safe and effective delivery system will offer unique advances to the field of inhaled medicine.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanopore and Nanochannel Transport Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, USA

Natural Products and Experimental Therapeutics Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, USA

Funding

National Institute of General Medical Sciences · Hawai‘i Community Foundation · Research Corporation of the University of Hawai’i · The Daniel K. Inouye College of Pharmacy

References (100+)

Show source-provided references
1. Adamcakova-Dodd A., Stebounova L.V., Kim J.S., Vorrink S.U., Ault A.P., O’shaughnessy P.T., Grassian V.H., Thorne P.S., Toxicity assessment of zinc oxide nanoparticles using sub-acute and sub-chronic murine inhalation models, Part Fibre Toxicol, 11 (2014) b1.10.1186/1743-8977-11-15 ↗
2. Adams K.E., Ke S., Kwon S., Liang F., Fan Z., Lu Y., Hirschi K., Mawad M.E., Barry M.A., Sevick-Muraca E.M., Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer, Journal of biomedical optics, 12 (2007) 024017-024017-024019.10.1117/1.2717137 ↗
3. Agrawal N., Dasaradhi P., Mohmmed A., Malhotra P., Bhatnagar R.K., Mukherjee S.K., RNA interference: Biology, mechanism, and applications, Microbiology and molecular biology reviews, 67 (2003) 657–685.10.1128/MMBR.67.4.657-685.2003 ↗
4. Agu R.U., Ugwoke M.I., Armand M., Kinget R., Verbeke N., The lung as a route for systemic delivery of therapeutic proteins and peptides, Respiratory research, 2 (2001) 198.10.1186/rr58 ↗
5. Amarzguioui M., Rossi J.J., Kim D., Approaches for chemically synthesized siRNA and vector-mediated RNAi, FEBS Letters, 579 (2005) 5974–5981.10.1016/j.febslet.2005.08.070 ↗
6. Amatngalim G.D., Van Wijck Y., De Mooij-Eijk Y., Verhoosel R.M., Harder J., Lekkerkerker A.N., Janssen R.A., Hiemstra P.S., Basal cells contribute to innate immunity of the airway epithelium through production of the antimicrobial protein rnase 7, J Immunol, 194 (2015) 3340–3350.10.4049/jimmunol.1402169 ↗
7. Ari A., Jet, ultrasonic, and mesh nebulizers: An evaluation of nebulizers for better clinical outcomes (2014).10.5152/ejp.2014.00087 ↗
8. Ari A., Hess D., Myers T., Rau J., A guide to aerosol delivery devices for respiratory therapists, Dallas, Texas: American Association for Respiratory Care (2009).
9. Ari A., Restrepo R.D., Aerosol delivery device selection for spontaneously breathing patients: 2012, Respiratory care, 57 (2012) 613–626.10.4187/respcare.01756 ↗
10. Arnold M.M., Gorman E.M., Schieber L.J., Munson E.J., Berkland C., NanoCipro encapsulation in monodisperse large porous PLGA microparticles, Journal of Controlled Release, 121 (2007) 100–109.10.1016/j.jconrel.2007.05.039 ↗
11. Arunthari V., Bruinsma R.S., Lee A.S., Johnson M.M., A prospective, comparative trial of standard and breath-actuated nebulizer: Efficacy, safety, and satisfaction, Respiratory care, 57 (2012) 1242–1247.10.4187/respcare.01450 ↗
12. Bai S., Gupta V., Ahsan F., Inhalable lactose-based dry powder formulations of low molecular weight heparin, Journal of aerosol medicine and pulmonary drug delivery, 23 (2010) 97–104.10.1089/jamp.2009.0745 ↗
13. Bally M.B., Harvie P., Wong F.M., Kong S., Wasan E.K., Reimer D.L., Biological barriers to cellular delivery of lipid-based DNA carriers, Advanced drug delivery reviews, 38 (1999) 291–315.10.1016/S0169-409X(99)00034-4 ↗
14. Bastacky J., Lee C., Goerke J., Koushafar H., Yager D., Kenaga L., Speed T.P., Chen Y., Clements J.A., Alveolar lining layer is thin and continuous: Low-temperature scanning electron microscopy of rat lung, Journal of Applied Physiology, 79 (1995) 1615–1628.10.1152/jappl.1995.79.5.1615 ↗
15. Ben-Jebria A., Eskew M.L., Edwards D.A., Inhalation system for pulmonary aerosol drug delivery in rodents using large porous particles, Aerosol Science & Technology, 32 (2000) 421–433.10.1080/027868200303551 ↗
16. Bisgaard H., O’callaghan C., Smaldone G.C., Drug delivery to the lung, CRC Press, 2001.10.1201/b14022 ↗
17. Bitko V., Musiyenko A., Shulyayeva O., Barik S., Inhibition of respiratory viruses by nasally administered siRNA, Nature medicine, 11 (2005) 50–55.10.1038/nm1164 ↗
18. Bivas-Benita M., Zwier R., Junginger H.E., Borchard G., Non-invasive pulmonary aerosol delivery in mice by the endotracheal route, European Journal of Pharmaceutics and Biopharmaceutics, 61 (2005) 214–218.10.1016/j.ejpb.2005.04.009 ↗
19. Bondesson E., Bengtsson T., Borgström L., Nilsson L.-E., Norrgren K., Trofast E., Wollmer P., Planar gamma scintigraphy—points to consider when quantifying pulmonary dry powder aerosol deposition, International journal of pharmaceutics, 258 (2003) 227–240.10.1016/S0378-5173(03)00148-0 ↗
20. Boussif O., Lezoualc’h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.-P., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine, Proceedings of the National Academy of Sciences, 92 (1995) 7297–7301.10.1073/pnas.92.16.7297 ↗
21. Burnett J.C., Rossi J.J., RNA-based therapeutics: Current progress and future prospects, Chemistry & biology, 19 (2012) 60–71.10.1016/j.chembiol.2011.12.008 ↗
22. Burns A.R., Smith C.W., Walker D.C., Unique structural features that influence neutrophil emigration into the lung, 2003.10.1152/physrev.00023.2002 ↗
23. Carvalho T.C., Peters J.I., Williams R.O. Iii, Influence of particle size on regional lung deposition—what evidence is there?, International Journal of Pharmaceutics, 406 (2011) 1–10.10.1016/j.ijpharm.2010.12.040 ↗
24. Chakravarty R., Hong H., Cai W., Positron emission tomography image-guided drug delivery: Current status and future perspectives, Molecular pharmaceutics, 11 (2014) 3777–3797.10.1021/mp500173s ↗
25. Chan H.-K., Formulation challenges: Protein powders for inhalation, Drugs and the Pharmaceutical Sciences, 126 (2003) 879–890.10.1201/9780203910337.ch74 ↗
26. Chan H.-K., Eberl S., Glover W., Radiolabeling of pharmaceutical aerosols and gamma scintigraphic imaging for lung deposition, Encyclopedia of Pharmaceutical Technology, 3rd ed. Informa Healthcare, New York, (2007) 3094–3107.
27. Chapters U.G., USP <601> Aerosols, nasal sprays, metered-dose inhalers and dry powder inhalers, USP 32-NF (2009).
28. Cherry S.R., Gambhir S.S., Use of positron emission tomography in animal research, ILAR journal, 42 (2001) 219–232.10.1093/ilar.42.3.219 ↗
29. Chiang P.-C., Alsup J.W., Lai Y., Hu Y., Heyde B.R., Tung D., Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery, Nanoscale research letters, 4 (2009) 254–261.10.1007/s11671-008-9234-1 ↗
30. Choi S.W., Lee S.H., Mok H., Park T.G., Multifunctional siRNA delivery system: Polyelectrolyte complex micelles of sixarm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide, Biotechnology progress, 26 (2010) 57–63.10.1002/btpr.310 ↗
31. Chougule M., Padhi B., Misra A., Development of spray dried liposomal dry powder inhaler of dapsone, AAPS PharmSciTech, 9 (2008) 47–53.10.1208/s12249-007-9024-6 ↗
32. Codrons V., Vanderbist F., Verbeeck R.K., Arras M., Lison D., Préat V., Vanbever R., Systemic delivery of parathyroid hormone (1–34) using inhalation dry powders in rats, Journal of pharmaceutical sciences, 92 (2003) 938–950.10.1002/jps.10346 ↗
33. Comsa D.C., Farrell T.J., Patterson M.S., Quantitative fluorescence imaging of point-like sources in small animals, Physics in medicine and biology, 53 (2008) 5797.10.1088/0031-9155/53/20/016 ↗
34. Conde J., Tian F., Hernandez Y., Bao C., Cui D., Janssen K.P., Ibarra M.R., Baptista P.V., Stoeger T., De La Fuente J.M., In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models, Biomaterials, 34 (2013) 7744–7753.10.1016/j.biomaterials.2013.06.041 ↗
35. Conway J., Lung imaging—two dimensional gamma scintigraphy, SPECT, CT and PET, Advanced drug delivery reviews, 64 (2012) 357–368.10.1016/j.addr.2012.01.013 ↗
36. Cryan S.-A., Sivadas N., Garcia-Contreras L., In vivo animal models for drug delivery across the lung mucosal barrier, Advanced drug delivery reviews, 59 (2007) 1133–1151.10.1016/j.addr.2007.08.023 ↗
37. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T., Nebulization of biodegradable nanoparticles: Impact of nebulizer technology and nanoparticle characteristics on aerosol features, Journal of Controlled Release, 86 (2003) 131–144.10.1016/S0168-3659(02)00370-X ↗
38. Dalby R., Spallek M., Voshaar T., A review of the development of respimat® soft mistTM inhaler, International journal of pharmaceutics, 283 (2004) 1–9.10.1016/j.ijpharm.2004.06.018 ↗
39. Dames P., Gleich B., Flemmer A., Hajek K., Seidl N., Wiekhorst F., Eberbeck D., Bittmann I., Bergemann C., Weyh T., Trahms L., Rosenecker J., Rudolph C., Targeted delivery of magnetic aerosol droplets to the lung, Nat Nanotechnol, 2 (2007) 495–499.10.1038/nnano.2007.217 ↗
40. Davies N.M., Feddah M.R., A novel method for assessing dissolution of aerosol inhaler products, International journal of pharmaceutics, 255 (2003) 175–187.10.1016/S0378-5173(03)00091-7 ↗
41. Daviskas E., Anderson S.D., Jaques A., Charlton B., Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis, CHEST Journal, 137 (2010) 861–868.10.1378/chest.09-2017 ↗
42. De Boer A.H., Gjaltema D., Hagedoorn P., Frijlink H.W., Characterization of inhalation aerosols: A critical evaluation of cascade impactor analysis and laser diffraction technique, Int J Pharm, 249 (2002) 219–231.10.1016/S0378-5173(02)00526-4 ↗
43. De Fougerolles A., Novobrantseva T., SiRNA and the lung: Research tool or therapeutic drug?, Current opinion in pharmacology, 8 (2008) 280–285.10.1016/j.coph.2008.04.005 ↗
44. De Fougerolles A., Vornlocher H.-P., Maraganore J., Lieberman J., Interfering with disease: A progress report on siRNA-based therapeutics, Nat Rev Drug Discov, 6 (2007) 443–453.10.1038/nrd2310 ↗
45. Denyer J., Dyche T., The adaptive aerosol delivery (AAD) technology: Past, present, and future, Journal of aerosol medicine and pulmonary drug delivery, 23 (2010) S-1–S-10.10.1089/jamp.2009.0791 ↗
46. Denyer J., Nikander K., Smith N., Adaptive aerosol delivery (AAD®) technology, Expert opinion on drug delivery, 1 (2004) 165–176.10.1517/17425247.1.1.165 ↗
47. Devincenzo J., Cehelsky J.E., Alvarez R., Elbashir S., Harborth J., Toudjarska I., Nechev L., Murugaiah V., Van Vliet A., Vaishnaw A.K., Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV), Antiviral research, 77 (2008) 225–231.10.1016/j.antiviral.2007.11.009 ↗
48. Devincenzo J., Lambkin-Williams R., Wilkinson T., Cehelsky J., Nochur S., Walsh E., Meyers R., Gollob J., Vaishnaw A., A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus, Proceedings of the National Academy of Sciences, 107 (2010) 8800–8805.10.1073/pnas.0912186107 ↗
49. Dhand R., Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol, Respiratory care, 47 (2002) 1406–1416; discussion 1416–1408.
50. Dickinson P.A., Howells S.W., Kellaway I.W., Novel nanoparticles for pulmonary drug administration, Journal of drug targeting, 9 (2001) 295–302.10.3109/10611860108997937 ↗
51. Dolovich M.B., 18f-fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery, Proceedings of the American Thoracic Society, 6 (2009) 477–485.10.1513/pats.200904-023AW ↗
52. Dolovich M.B., Dhand R., Aerosol drug delivery: Developments in device design and clinical use, The Lancet, 377 (2011) 1032–1045.10.1016/S0140-6736(10)60926-9 ↗
53. Driscoll K.E., Costa D.L., Hatch G., Henderson R., Oberdorster G., Salem H., Schlesinger R.B., Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: Uses and limitations, Toxicological Sciences, 55 (2000) 24–35.10.1093/toxsci/55.1.24 ↗
54. Dunbar C., Mitchell J., Analysis of cascade impactor mass distributions, Journal of Aerosol Medicine-Deposition Clearance and Effects in the Lung, 18 (2005) 439–451.10.1089/jam.2005.18.439 ↗
55. Eberl S., Chan H.-K., Daviskas E., SPECT imaging for radioaerosol deposition and clearance studies, Journal of aerosol medicine, 19 (2006) 8–20.10.1089/jam.2006.19.8 ↗
56. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R., Large porous particles for pulmonary drug delivery, Science, 276 (1997) 1868–1872.10.1126/science.276.5320.1868 ↗
57. Elhissi A., Karnam K.K., Danesh-Azari M.R., Gill H.S., Taylor K.M., Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers, Journal of pharmacy and pharmacology, 58 (2006) 887–894.10.1211/jpp.58.7.0002 ↗
58. Elhissi A., Taylor K., Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers, Journal of drug delivery science and technology, 15 (2005) 261–265.10.1016/S1773-2247(05)50047-9 ↗
59. Eshel G., Levy G., Mingelgrin U., Singer M., Critical evaluation of the use of laser diffraction for particle-size distribution analysis, Soil Science Society of America Journal, 68 (2004) 736–743.10.2136/sssaj2004.7360 ↗
60. Everard M.L., Studies using radiolabelled aerosols in children, Thorax, 49 (1994) 1259–1266.10.1136/thx.49.12.1259 ↗
61. Feddah M.R., Brown K.F., Gipps E.M., Davies N.M., In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: Influence of inspiratory flow rates, J Pharm Pharm Sci, 3 (2000) 318–324.
62. Fellmann C., Lowe S.W., Stable RNA interference rules for silencing, Nature cell biology, 16 (2014) 10–18.10.1038/ncb2895 ↗
63. Fernandes C.A., Vanbever R., Preclinical models for pulmonary drug delivery, Expert opinion on drug delivery, 6 (2009) 1231–1245.10.1517/17425240903241788 ↗
64. Ferrari S., Kitson C., Farley R., Steel R., Marriott C., Parkins D., Scarpa M., Wainwright B., Evans M., Colledge W., Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium, Gene therapy, 8 (2001) 1380–1386.10.1038/sj.gt.3301525 ↗
65. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C., Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans, Nature, 391 (1998) 806–811.10.1038/35888 ↗
66. Fleming J., Conway J., Majoral C., Tossici-Bolt L., Katz I., Caillibotte G., Perchet D., Pichelin M., Muellinger B., Martonen T., The use of combined single photon emission computed tomography and X-ray computed tomography to assess the fate of inhaled aerosol, Journal of aerosol medicine and pulmonary drug delivery, 24 (2011) 49–60.10.1089/jamp.2010.0843 ↗
67. Frauenfelder T., Kestenholz P., Hunziker R., Nguyen T.D.L., Fries M., Veit-Haibach P., Husmann L., Stahel R., Weder W., Opitz I., Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma, Journal of computer assisted tomography, 39 (2015) 160–165.10.1097/RCT.0000000000000174 ↗
68. Fulton A., Peters S.T., Perkins G.A., Jarosinski K.W., Damiani A., Brosnahan M., Buckles E.L., Osterrieder N., Van De Walle G.R., Effective treatment of respiratory alphaherpesvirus infection using RNA interference, PLoS One, 4 (2009) e4118.10.1371/journal.pone.0004118 ↗
69. Garbuzenko O.B., Saad M., Betigeri S., Zhang M., Vetcher A.A., Soldatenkov V.A., Reimer D.C., Pozharov V.P., Minko T., Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug, Pharmaceutical Research, 26 (2009) 382–394.10.1007/s11095-008-9755-4 ↗
70. Ghosn B., Singh A., Li M., Vlassov A.V., Burnett C., Puri N., Roy K., Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA, Oligonucleotides, 20 (2010) 163–172.10.1089/oli.2010.0235 ↗
71. Greene C.M., Mcelvaney N.G., Proteases and antiproteases in chronic neutrophilic lung disease-relevance to drug discovery, British journal of pharmacology, 158 (2009) 1048–1058.10.1111/j.1476-5381.2009.00448.x ↗
72. Groneberg D., Eynott P., Lim S., Oates T., Wu R., Carlstedt I., Roberts P., Mccann B., Nicholson A., Harrison B., Expression of respiratory mucins in fatal status asthmaticus and mild asthma, Histopathology, 40 (2002) 367–373.10.1046/j.1365-2559.2002.01378.x ↗
73. Gunther M., Lipka J., Malek A., Gutsch D., Kreyling W., Aigner A., Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung, Eur J Pharm Biopharm, 77 (2011) 438–449.10.1016/j.ejpb.2010.11.007 ↗
74. Gutbier B., Kube S.M., Reppe K., Santel A., Lange C., Kaufmann J., Suttorp N., Witzenrath M., RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice, Pulmonary pharmacology & therapeutics, 23 (2010) 334–344.10.1016/j.pupt.2010.03.007 ↗
75. Hannon G.J., RNA interference, Nature, 418 (2002) 244–251.10.1038/418244a ↗
76. Hanson L.R., Frey W.H., 2nd, Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease, BMC Neurosci, 9 Suppl 3 (2008) S5.10.1186/1471-2202-9-S3-S5 ↗
77. Haynes J.M., Randomized controlled trial of a breath-activated nebulizer in patients with exacerbation of COPD, Respiratory care, 57 (2012) 1385–1390.10.4187/respcare.01609 ↗
78. Heyder J., Gebhart J., Rudolf G., Schiller C.F., Stahlhofen W., Deposition of particles in the human respiratory tract in the size range 0.005–15 μm, Journal of Aerosol Science, 17 (1986) 811–825.10.1016/0021-8502(86)90035-2 ↗
79. Hibbitts A., O’mahony A.M., Forde E., Nolan L., Ogier J., Desgranges S., Darcy R., Macloughlin R., O’driscoll C.M., Cryan S.A., Early-stage development of novel cyclodextrin-siRNA nanocomplexes allows for successful postnebulization transfection of bronchial epithelial cells, J Aerosol Med Pulm Drug Deliv, 27 (2014) 466–477.10.1089/jamp.2013.1045 ↗
80. Hickey A.J., Pharmaceutical inhalation aerosol technology, CRC Press, 2003.10.1201/9780203912898 ↗
81. Hickey A.J., Garcia-Contreras L., Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: Relevance to humans, Critical ReviewsTM in Therapeutic Drug Carrier Systems, 18 (2001).10.1615/CritRevTherDrugCarrierSyst.v18.i4.20 ↗
82. Hill D.B., Vasquez P.A., Mellnik J., Mckinley S.A., Vose A., Mu F., Henderson A.G., Donaldson S.H., Alexis N.E., Boucher R.C., A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease, PloS one, 9 (2014) e87681.10.1371/journal.pone.0087681 ↗
83. Hinchcliffe M., Illum L., Intranasal insulin delivery and therapy, Adv Drug Deliv Rev, 35 (1999) 199–234.
84. Ho S.L., Kwong W.J., O’drowsky L., Coates A.L., Evaluation of four breath-enhanced nebulizers for home use, Journal of aerosol medicine, 14 (2001) 467–475.10.1089/08942680152744677 ↗
85. Hochrainer D., Hölz H., Kreher C., Scaffidi L., Spallek M., Wachtel H., Comparison of the aerosol velocity and spray duration of respimat® soft mistTM inhaler and pressurized metered dose inhalers, Journal of aerosol medicine, 18 (2005) 273–282.10.1089/jam.2005.18.273 ↗
86. Hosoya K., Satoh T., Yamamoto Y., Saeki K., Igawa K., Okano M., Moriya T., Imamura O., Nemoto Y., Yokozeki H., Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis, Allergy, 66 (2011) 124–131.10.1111/j.1398-9995.2010.02440.x ↗
87. Howard K.A., Rahbek U.L., Liu X., Damgaard C.K., Glud S.Z., Andersen M.O., Hovgaard M.B., Schmitz A., Nyengaard J.R., Besenbacher F., Kjems J., RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system, Mol Ther, 14 (2006) 476–484.10.1016/j.ymthe.2006.04.010 ↗
88. Huchon G.J., Montgomery A.B., Lipavsky A., Hoeffel J.M., Murray J.F., Respiratory clearance of aerosolized radioactive solutes of varying molecular weight, Journal of nuclear medicine: official publication, Society of Nuclear Medicine, 28 (1987) 894–902.
89. Kamei N., Takeda-Morishita M., Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides, J Control Release, 197 (2015) 105–110.10.1016/j.jconrel.2014.11.004 ↗
90. Kanasty R., Dorkin J.R., Vegas A., Anderson D., Delivery materials for siRNA therapeutics, Nature materials, 12 (2013) 967–977.10.1038/nmat3765 ↗
91. Khalil I.A., Kogure K., Akita H., Harashima H., Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery, Pharmacological reviews, 58 (2006) 32–45.10.1124/pr.58.1.8 ↗
92. Kim D.H., Rossi J.J., Strategies for silencing human disease using RNA interference, Nature Reviews Genetics, 8 (2007) 173–184.10.1038/nrg2006 ↗
93. Kishore U., Greenhough T.J., Waters P., Shrive A.K., Ghai R., Kamran M.F., Bernal A.L., Reid K.B., Madan T., Chakraborty T., Surfactant proteins SP-A and SP-D: Structure, function and receptors, Mol Immunol, 43 (2006) 1293–1315.10.1016/j.molimm.2005.08.004 ↗
94. Knowles M.R., Boucher R.C., Mucus clearance as a primary innate defense mechanism for mammalian airways, The Journal of clinical investigation, 109 (2002) 571–577.10.1172/JCI0215217 ↗
95. Kolaczkowska E., Kubes P., Neutrophil recruitment and function in health and inflammation, Nat Rev Immunol, 13 (2013) 159–175.10.1038/nri3399 ↗
96. Komlosi P., Altes T.A., Qing K., Mooney K.E., Miller G.W., Mata J.F., De Lange E.E., Tobias W.A., Cates G.D., Brookeman J.R., Regional anisotropy of airspace orientation in the lung as assessed with hyperpolarized helium-3 diffusion MRI, Journal of Magnetic Resonance Imaging (2015).10.1002/jmri.24950 ↗
97. Koping-Hoggard M., Issa M.M., Kohler T., Tronde A., Varum K.M., Artursson P., A miniaturized nebulization catheter for improved gene delivery to the mouse lung, J Gene Med, 7 (2005) 1215–1222.10.1002/jgm.762 ↗
98. Kovar J.L., Simpson M.A., Schutz-Geschwender A., Olive D.M., A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models, Analytical biochemistry, 367 (2007) 1–12.10.1016/j.ab.2007.04.011 ↗
99. Kruger S.J., Niles D.J., Dardzinski B., Harman A., Jarjour N.N., Ruddy M., Nagle S.K., Francois C.J., Sorkness R.L., Burton R.M., Hyperpolarized helium-3 MRI of exercise-induced bronchoconstriction during challenge and therapy, Journal of Magnetic Resonance Imaging, 39 (2014) 1230–1237.10.1002/jmri.24272 ↗
100. Kuroki Y., Takahashi M., Nishitani C., Pulmonary collectins in innate immunity of the lung, Cellular microbiology, 9 (2007) 1871–1879.10.1111/j.1462-5822.2007.00953.x ↗